Abstract
Pancreatic exocrine insufficiency with steatorrhea is a major consequence of pancreatic diseases (eg, chronic pancreatitis, cystic fibrosis, severe acute necrotizing pancreatitis, pancreatic cancer), extrapancreatic diseases such as celiac disease and Crohn’s disease, and gastrointestinal and pancreatic surgical resection. Recognition of this entity is highly relevant to avoid malnutrition-related morbidity and mortality. Therapy for pancreatic exocrine insufficiency is based on the oral administration of pancreatic enzymes aiming at providing the duodenal lumen with sufficient active lipase at the time of gastric emptying of nutrients. Administration of enzymes in the form of enteric-coated minimicrospheres avoids acid-mediated lipase inactivation and ensures gastric emptying of enzymes in parallel with nutrients. Nevertheless, such factors as acidic intestinal pH and bacterial overgrowth may prevent normalization of fat digestion even in compliant patients. The present article critically reviews current therapeutic approaches to pancreatic exocrine insufficiency.
Similar content being viewed by others
References and Recommended Reading
Layer P, Go VLW, DiMagno EP: Fate of pancreatic enzymes during aboral small intestinal transit in humans. Am J Physiol 1986, 251:G475–G480.
Holtmann G, Nelly DG, Sternby B, DiMagno EP: Survival of human pancreatic enzymes during small bowel transit: effects of nutrients, bile acids and enzymes. Am J Physiol 1997, 273:G553–G558.
DiMagno EP, Malagelada JR, Go VLW, Moertel CG: Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two dosage schedules. N Engl J Med 1977, 296:1318–1322.
DiMagno EP, Go VLW, Summerskill WHJ: Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973, 288:813–815.
Lankisch PG, Lembcke B, Wemken G, Creutzfeldt W: Functional reserve capacity of the exocrine pancreas. Digestion 1986, 35:175–181.
Carriere F, Renou C, Ransac S, et al.: Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol 2001, 281:G16–G28.
Carriere F, Renou C, Lopez V, et al.: The specific activities of human digestive lipases measured from in vivo and in vitro lipolysis of test meals. Gastroenterology 2000, 119:949–960.
Carriere F, Grandval P, Renou C, et al.: Quantitative study of digestive enzyme secretion and gastrointestinal lipolysis in chronic pancreatitis. Clin Gastroenterol Hepatol 2005, 3:28–38.
Carriere F, Grandval P, Gregory PC, et al.: Does the pancreas really produce much more lipase than required for fat digestion? JOP 2005, 6:206–215.
Ihse I, Arnesjo B, Kugelberg C, et al.: Intestinal activities of trypsin, lipase, and phospholipase after a test meal. An evaluation of 474 examinations. Scand J Gastroenterol 1977, 12:663–668.
DiMagno EP, Malagelada JR, Go VLW: Relationship between alcoholism and pancreatic insufficiency. Ann N Y Acad Sci 1975, 252:200–207.
Mizuno R, Hayakawa T, Noda A: Elastase secretion in pancreatic disease. Am J Gastroenterol 1985, 80:113–117.
Montalto G, Zorreéis M, Carroccio A, et al.: Lipoproteins and chronic pancreatitis. Pancreas 1994, 9:137–138.
Domínguez-Muñoz JE: Management of maldigestion in chronic pancreatitis: a practical protocol. In Clinical Pancreatology for Practising Gastroenterologists and Surgeons. Edited by Domínguez-Muñoz JE, Oxford: Blackwell Publishing; 2005:288–293.
Domínguez-Muñoz JE, Iglesias-García J, Vilariño-Insua M, Iglesias-Rey M: 13C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis. Clin Gastroenterol Hepatol, in press.
Gullo L, Barbara L, Labò G: Effect of cessation of alcohol use on the course of pancreatic dysfunction in alcoholic pancreatitis. Gastroenterology 1988, 95:1063–1068.
Thiruvengadam R, DiMagno EP: Inactivation of human lipase by proteases. Am J Physiol 1988, 255:G476–G481.
Suzuki A, Mizumoto A, Rerknimitr R, et al.: Effect of bacterial or porcine lipase with low-or high-fat diets on nutrient absorption in pancreatic insufficient dogs. Gastroenterology 1999, 116:431–437.
Isaksson G, Lundquist I, Ihse I: Effect of dietary fiber on pancreatic enzyme activity in vitro. Gastroenterology 1982, 82:918–924.
Keller J, Layer P: Human pancreatic exocrine response to nutrients in health and disease. Gut 2005, 54(Suppl 6):1–28.
Layer P, Keller J, Lankisch PG: Pancreatic enzyme replacement therapy. Curr Gastroenterol Rep 2001, 3:101–108.
Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M, et al.: Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: a randomized, three-way crossover study. Aliment Pharmacol Ther 2005, 21:993–1000.
McColl KE, el-Omar E, Gillen D: Helicobacter pylori gastritis and gastric physiology. Gastroenterol Clin North Am 2000, 29:687–703.
Hamler A, Olbe L: The influence of Helicobacter pylori infection on postprandial duodenal acid load and duodenal bulb pH in humans. Gastroenterology 1996, 111:391–400.
Regan PT, Malagelada JR, DiMagno EP, et al.: Comparative effects of anacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency. N Engl J Med 1977, 297:854–858.
Dutta SK, Rubin J, Harvey J: Comparative evaluation of the therapeutic efficacy of a pH-sensitive enteric coated pancreatic enzyme preparation with conventional pancreatic enzyme therapy in the treatment of exocrine pancreatic insufficiency. Gastroenterology 1983, 84:476–482.
Dutta SK, Hubbard VS, Appler M: Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis. Dig Dis Sci 1988, 33:1237–1244.
Delchier JC, Vidon N, Saint-Marc Girandin MF, et al.: Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two pancreatic enzyme preparations. Aliment Pharmacol Ther 1991, 5:365–378.
Stead RJ, Skypala I, Hodson ME, Batten JC: Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric coated preparation. Thorax 1987, 42:533–537.
Kuhnelt P, Mundlos S, Adler G: Effect of pellet size of a pancreas enzyme preparation on duodenal lipolytic activity. Z Gastroenterol 1991, 29:417–421.
Halm U, Löser C, Löhr M, et al.: A double-blind, randomized, multicentre, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency. Aliment Pharmacol Ther 1999, 13:951–957.
Safdi M, Bekal PK, Martin S, et al.: The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. Pancreas 2006, 33:156–162.
Stern RC, Eisenberg JD, Wagener JS, et al.: A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. Am J Gastroenterol 2000, 95:1932–1938.
Domínguez-Muñoz JE, Iglesias-García J, Iglesias-Rey M, Vilariño-Insua: Optimizing the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric-coated pancreatic extracts. Gut 2006, 55:1056–1057.
Guarner L, Rodriguez R, Guarner F, Malagelada JR: Fate of oral enzymes in pancreatic insufficiency. Gut 1993, 34:708–712.
Casellas F, Guarner L, Vaquero E, et al.: Hydrogen breath test with glucose in exocrine pancreatic insufficiency. Pancreas 1998, 16:481–486.
Pieramico O, Dominguez-Munoz JE, Nelson DK, et al.: Interdigestive cycling in chronic pancreatitis: altered coordination among pancreatic secretion, motility, and hormones. Gastroenterology 1995, 109:224–230.
Bruno MJ, Rauws EAJ, Hoek FJ, Tytgat GNJ: Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy. Dig Dis Sci 1994, 39:988–992.
Lankisch PG, Lembcke B, Goke B, Creutzfeldt W: Therapy of pancreatogenic steatorrhea: does acid protection of pancreatic enzymes offer any advantage? Z Gastroenterol 1986, 24:753–757.
Carroccio A, Pardo F, Montalto G, et al.: Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy: a long-term study in cystic fibrosis. Dig Dis Sci 1992, 37:1441–1446.
Proesmans M, DeBoeck K: Omeprazole, a proton pump inhibitor, improves residual steatorrhea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur J Pediatr 2003, 162:760–763.
Kalnins D, Ellis L, Corey M, et al.: Enteric-coated enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis. J Pediatr Gastroenterol Nutr 2006, 42:256–261.
Brady MS, Garson JL, Krug SK, et al.: An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study. J Am Diet Assoc 2006, 106:1181–1186.
Friess H, Bohm J, Muller MW, et al.: Maldigestion after total gastrectomy is associated with pancreatic insufficiency. Am J Gastroenterol 1996, 91:341–347.
Yamaguchi K, Yokohata K, Nakano K, et al.: Which is a less invasive pancreatic head resection: PD, PPPD, or DPPHR? Dig Dis Sci 2001, 46:282–288.
Lankisch PG: Appropriate pancreatic function tests and indication for pancreatic enzyme therapy following surgical procedures on the pancreas. Pancreatology 2001, 1(Suppl 1):14–26.
Braga M, Cristallo M, De Franchis R, et al.: Pancreatic enzyme replacement therapy in post-pancreatectomy patients. Int J Pancreatol 1989, 5(Suppl):37–44.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Domínguez-Muñoz, J.E. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep 9, 116–122 (2007). https://doi.org/10.1007/s11894-007-0005-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11894-007-0005-4